1st Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
—
Expenses
$670,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process.

LobbyistCovered position, as disclosed
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Issues related to corporate and international tax policy and research and development tax credits.

LobbyistCovered position, as disclosed
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Issues related to funding for the Food and Drug Administration - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act; General education about policies to improve outcomes for patients with APOL-1 kidney disease.

LobbyistCovered position, as disclosed
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines.

LobbyistCovered position, as disclosed
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.